Avelumab
Approved medicineAlso known as Bavencio.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: AVELUMAB (BLA761049)
Label change: AVELUMAB (BLA761049)
Label change: AVELUMAB (BLA761049)
Indication expansion: AVELUMAB (BLA761049)
Efficacy and immune-related adverse event associations in avelumab-treated patients.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the… Show full indicationShow less
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal for immunotherapy of cancer3
- JAMA oncology2
- Annals of oncology : official journal of the European Society for Medical Oncology1
- ESMO open1
- Future oncology (London, England)1
- The Lancet. Oncology1
- D'Angelo SP7
- Lebbé C6
- Bajars M4
- Terheyden P4
- Bhatia S3
- Brownell I3
- Grob JJ3
- Güzel G3
- Memorial Sloan Kettering Cancer Center6
- Dana-Farber Cancer Institute4
- Rutgers Cancer Institute of New Jersey4
- University of Lübeck4
- University of Washington Medical Center at South Lake Union4
- Aix-Marseille University3
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Avelumab in the shared literature.
Studied across 4 of the same disease areas as Avelumab in the shared literature.
Studied across 3 of the same disease areas as Avelumab in the shared literature.
Studied across 3 of the same disease areas as Avelumab in the shared literature.
Studied across 3 of the same disease areas as Avelumab in the shared literature.
Studied across 2 of the same disease areas as Avelumab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.